Mostrar el registro sencillo del ítem

Lipid-based nanoformulations in the treatment of neurological disorders

dc.contributor.authorPottoo F.H.
dc.contributor.authorSharma S.
dc.contributor.authorJaved M.N.
dc.contributor.authorBarkat M.A.
dc.contributor.authorHarshita
dc.contributor.authorAlam M.S.
dc.contributor.authorNaim M.J.
dc.contributor.authorAlam O.
dc.contributor.authorAnsari M.A.
dc.contributor.authorBarreto G.E.
dc.contributor.authorAshraf G.M.
dc.date.accessioned2020-09-02T22:25:55Z
dc.date.available2020-09-02T22:25:55Z
dc.date.issued2020
dc.identifier10.1080/03602532.2020.1726942
dc.identifier.citation52, 1, 185-204
dc.identifier.issn03602532
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5836
dc.descriptionThe neurological disorders affect millions of people worldwide, and are bracketed as the foremost basis of disability-adjusted life years (DALYs). The treatment options are symptomatic and often the movement of drugs is restricted by a specialized network of endothelial cell layers (adjoined by tight cell-to-cell junction proteins; occludin, claudins, and junctional adhesion molecules), pericytes and astroglial foot processes. In recent years, advances in nanomedicine have led to therapies that target central nervous system (CNS) pathobiology via altering signaling mechanisms such as activation of PI3K/Akt pathway in ischemic stroke arrests apoptosis, interruption of α-synuclein aggregation prevents neuronal degeneration in Parkinson’s. Often such interactions are limited by insufficient concentrations of drugs reaching neuronal tissues and/or insufficient residence time of drug/s with the receptor. Hence, lipid nanoformulations, SLNs (solid lipid nanoparticles) and NLCs (nanostructured lipid carriers) emerged to overcome these challenges by utilizing physiological transport mechanisms across blood–brain barrier, such as drug-loaded SLN/NLCs adsorb apolipoproteins from the systemic circulation and are taken up by endothelial cells via low-density lipoprotein (LDL)-receptor mediated endocytosis and subsequently unload drugs at target site (neuronal tissue), which imparts selectivity, target ability, and reduction in toxicity. This paper reviews the utilization of SLN/NLCs as carriers for targeted delivery of novel CNS drugs to improve the clinical course of neurological disorders, placing some additional discussion on the metabolism of lipid-based formulations. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
dc.language.isoen
dc.publisherTaylor and Francis Ltd
dc.subjectBlood–brain barrier
dc.subjectbrain-targeted drug delivery systems
dc.subjectCNS
dc.subjectdrug metabolism
dc.subjectdrug targeting
dc.subjectlipid nanoparticles
dc.subjectneurological disorders
dc.subjectlipid
dc.subjectnanocarrier
dc.subjectsolid lipid nanoparticle
dc.subjectlipid
dc.subjectnanoparticle
dc.subjectAlzheimer disease
dc.subjectblood brain barrier
dc.subjectbrain ischemia
dc.subjectdrug delivery system
dc.subjectepilepsy
dc.subjecthuman
dc.subjectlipid metabolism
dc.subjectlipid transport
dc.subjectmicroemulsion
dc.subjectmicrofluidics
dc.subjectnanomedicine
dc.subjectnanotechnology
dc.subjectneurologic disease
dc.subjectnonhuman
dc.subjectparkinsonism
dc.subjectReview
dc.subjectanimal
dc.subjectchemistry
dc.subjectmetabolism
dc.subjectneurologic disease
dc.subjectprocedures
dc.subjectAnimals
dc.subjectBlood-Brain Barrier
dc.subjectDrug Delivery Systems
dc.subjectHumans
dc.subjectLipids
dc.subjectNanoparticles
dc.subjectNervous System Diseases
dc.titleLipid-based nanoformulations in the treatment of neurological disorders
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85081404106.pdf
Tamaño:
3.673Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem